BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 31207152)

  • 1. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
    Calabrese LH; Abud-Mendoza C; Lindsey SM; Lee SH; Tatulych S; Takiya L; Iikuni N; Soma K; Luo Z; Fleischmann R
    Arthritis Care Res (Hoboken); 2020 Mar; 72(3):353-359. PubMed ID: 31207152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
    Curtis JR; Xie F; Yang S; Bernatsky S; Chen L; Yun H; Winthrop K
    Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1249-1254. PubMed ID: 30295428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
    Fleischmann R; Mysler E; Hall S; Kivitz AJ; Moots RJ; Luo Z; DeMasi R; Soma K; Zhang R; Takiya L; Tatulych S; Mojcik C; Krishnaswami S; Menon S; Smolen JS;
    Lancet; 2017 Jul; 390(10093):457-468. PubMed ID: 28629665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.
    Winthrop KL; Wouters AG; Choy EH; Soma K; Hodge JA; Nduaka CI; Biswas P; Needle E; Passador S; Mojcik CF; Rigby WF
    Arthritis Rheumatol; 2017 Oct; 69(10):1969-1977. PubMed ID: 28845577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
    Kivitz AJ; Cohen S; Keystone E; van Vollenhoven RF; Haraoui B; Kaine J; Fan H; Connell CA; Bananis E; Takiya L; Fleischmann R
    Semin Arthritis Rheum; 2018 Dec; 48(3):406-415. PubMed ID: 30177460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
    Curtis JR; Xie F; Yun H; Bernatsky S; Winthrop KL
    Ann Rheum Dis; 2016 Oct; 75(10):1843-7. PubMed ID: 27113415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.
    Winthrop KL; Yamanaka H; Valdez H; Mortensen E; Chew R; Krishnaswami S; Kawabata T; Riese R
    Arthritis Rheumatol; 2014 Oct; 66(10):2675-84. PubMed ID: 24943354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
    Takeuchi T; Fleischmann R; Iikuni N; Shi H; Soma K; Paulissen J; Hirose T; Smolen JS
    Arthritis Res Ther; 2021 Aug; 23(1):220. PubMed ID: 34429160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
    Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
    Strand V; Mysler E; Moots RJ; Wallenstein GV; DeMasi R; Gruben D; Soma K; Iikuni N; Smolen JS; Fleischmann R
    RMD Open; 2019; 5(2):e001040. PubMed ID: 31673419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
    Winthrop KL; Curtis JR; Lindsey S; Tanaka Y; Yamaoka K; Valdez H; Hirose T; Nduaka CI; Wang L; Mendelsohn AM; Fan H; Chen C; Bananis E
    Arthritis Rheumatol; 2017 Oct; 69(10):1960-1968. PubMed ID: 28845604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
    Takeuchi T; Yamanaka H; Yamaoka K; Arai S; Toyoizumi S; DeMasi R; Fukuma Y; Hirose T; Sugiyama N; Zwillich SH; Tanaka Y
    Mod Rheumatol; 2019 Sep; 29(5):756-766. PubMed ID: 30489177
    [No Abstract]   [Full Text] [Related]  

  • 14. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
    Bechman K; Subesinghe S; Norton S; Atzeni F; Galli M; Cope AP; Winthrop KL; Galloway JB
    Rheumatology (Oxford); 2019 Oct; 58(10):1755-1766. PubMed ID: 30982883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.
    Chen DY; Hsu PN; Tang CH; Claxton L; Valluri S; Gerber RA
    J Med Econ; 2019 Aug; 22(8):777-787. PubMed ID: 30982378
    [No Abstract]   [Full Text] [Related]  

  • 16. Tofacitinib: A Review in Rheumatoid Arthritis.
    Dhillon S
    Drugs; 2017 Dec; 77(18):1987-2001. PubMed ID: 29139090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL; Melmed GY; Vermeire S; Long MD; Chan G; Pedersen RD; Lawendy N; Thorpe AJ; Nduaka CI; Su C
    Inflamm Bowel Dis; 2018 Sep; 24(10):2258-2265. PubMed ID: 29850873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.
    Genovese MC; van Vollenhoven RF; Wilkinson B; Wang L; Zwillich SH; Gruben D; Biswas P; Riese R; Takiya L; Jones TV
    Arthritis Res Ther; 2016 Jun; 18():145. PubMed ID: 27334658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tofacitinib versus methotrexate in rheumatoid arthritis.
    Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
    N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
    Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
    Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.